Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,401–1,500 of 1,676
Wu, M., Zhang, J., Xu, Y., Wang, Y., Deng, F., & Chen, X. (2017) · Biomedical Research-tokyo · Cited by 1
Parhofer, K. G. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0233-7 · Cited by 1
Fettstoffwechselstörungen: Diagnostik und Therapie
Sinning, D., & Landmesser, U. (2017) · Herz · doi:10.1007/s00059-017-4601-2 · Cited by 2
Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles
Feldman, R. D., FITCHETT, D. H., Hegele, R. A., & Poulter, N. R. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.091 · Cited by 1
Zawadzki, N. K., & Hay, J. W. (2019) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2019.132 · Cited by 2
Allayee, H. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100064 · Cited by 1
Addressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Effects of omega-3 fatty acids, vitamins, and chelation therapy in patients with heart diseases
Joo, S.-J. (2021) · Journal of Medicine and Life Science · doi:10.22730/jmls.2021.18.1.1 · Cited by 1
Premyodhin, N., Fan, W., Younus, M., Harrington, D. S., & Wong, N. D. (2021) · Coronary Artery Disease · doi:10.1097/mca.0000000000001076 · Cited by 1
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-3 · Cited by 1
Therapy of Elevated Lipoprotein(a)
Ibrahim, S., & Stroes, E. S. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_21 · Cited by 2
Correlation between renal metabolism and cardiovascular disease
Deng, S., & Huang, W. (2023) · Metabolism and Translational Medicine · doi:10.54844/mtm.2023.0351 · Cited by 1
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_58 · Cited by 1
Clarke, R., & Baigent, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00071-0 · Cited by 1
Strengthening the Achilles Heel of High-Risk Plaques∗
Moreno, P. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.032 · Cited by 2
“Furthermore, successful pharmacologic efforts to increase HDL-C (up to 70%) showed no benefit and possible harm to patients (26,27).”
BackgroundPCSK9 Inhibition: Does Lipoprotein Size Matter?
Si‐Tayeb, K., & Cariou, B. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002806 · Cited by 1
Ezetimibe–Statin Combination to Reduce Cardiovascular Events: The Evidence Base
Jialal, I., & Abate, N. I. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.29000.jia · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Rhainds, D., Brodeur, M. R., Rautureau, Y., & Tardif, J. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx496 · Cited by 1
Genetic variation in apolipoprotein A-I concentrations and risk of coronary artery diseasePreprint
Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M. A. P., Lehtimäki, T. J., Havulinna, A. S., Kristiansson, K., Salomaa, V. V., Perola, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/576504 · Cited by 1
“This approach included the use of the following estimates: [1] per-allele effect estimate (in g/L) for the association between rs12225230 and apoA-I (meta-analyzed result between the Finnish individual participant data (IPD) and a prior GWAS30; total N=37,093); [2] per-allele effect estimates All rights reserved.”
MethodA vitaminic boost to rock the aortic wall
Caligiuri, G. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa329 · Cited by 1
Atherosclerosis: Cholesterol Management
Edmondson, S. D., Burnett, D. A., & Davis, H. R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc185.pub2 · Cited by 1
Sokołowska, M., Rovati, G. E., Diamant, Z., et al. (2021) · doi:10.22541/au.163790432.20160380/v1 · Cited by 1
Drug Therapy: Special Considerations in Diabetes
Cheung, B. M. Y., & Ronald, C. W. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch28 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Zou, X., Li, Z., WAN, X., Sun, S., Wang, S., Qu, N., Zhang, Y., Lu, R., Li, Z., Yang, L. M., et al. (2022) · SSRN Electronic Journal · doi:10.22541/au.170669100.03220590/v1 · Cited by 1
Hypothalamic Gliosis is Associated With Multiple Cardiovascular Disease Risk FactorsPreprint
Lo, J., Melhorn, S. J., Kee, S., Olerich, K. L. W., Huang, A., Yeum, D., Beiser, A., Seshadri, S. S., DeCarli, C. S., & Schur, E. A. (2024) · medRxiv · doi:10.1101/2024.09.19.24313914 · Cited by 1
HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE
Nicholls, S. J., Brown, H., & Bubb, K. J. (2020) · EMJ Cardiology · doi:10.33590/emjcardiol/20-00038 · Cited by 1
Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy
Kataoka, Y., & Nicholls, S. J. (2014) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.20.033
Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence
Jimenez, J. G., & Haft, G. (2014) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s50952 · Cited by 1
Tietge, U. J. F. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000164
Stärken und Grenzen randomisierter Studien zur Lipidtherapie
Windler, E. E. T., Klose, G., Parhofer, K. G., & Steinhagen‐Thiessen, E. (2014) · CardioVasc · doi:10.1007/s15027-014-0520-9
Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness
Dai, H., Xue-feng, G., & Xiao, Z. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.004
Niacin–laropiprant fails to reduce the risk of vascular events
Huynh, K. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.116
Is Low HDL Cholesterol a Marker or a Mediator of Cardiovascular Disease
Yassine, H. N. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_5
Durrington, P. N. (2014) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2014-110084
Combination pharmacotherapy in lipid management
Lee, S. (2015) · Journal of Korean Medical Association · doi:10.5124/jkma.2015.58.8.745
“하지만 2011년 과 2014년에 발표된 AIM-HIGH 연구와[5] HPS2-THRIVE 연구에서[18] 각각 스타틴-니코틴산 병합요법과 스타틴-니 코틴산-라로피프란트 (홍조억제제) 병합요법이 스타틴 단독 요법에 비해 심혈관 위험도를 추가적으로 줄이지 못했으며, 후자의 경우에는 부작용을 유의하게 증가시켜서 이 병합요법 의 입지는 상당히 좁아지는 모양새다.”
Hyperlipidemia: Where Is the Evidence for Combination Therapy?
Tannock, L. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch26
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Hypertriglyceridemia: Should We Treat?
Brinton, E. A. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch27
Immediate release niacin effect at stratified lipid levels
Vo, E., & Goldberg, S. J. (2015) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2015.10.004
Fibrates: From PPARα activation to clinical use in the metabolic syndrome
(2020) · doi:10.5348/b01-2015-3-ra-3
“Similarly, the Heart Protection Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study was designed to investigate the benefits of adding niacin (in combination with laropiprant, a prostaglandin D2 antagonist to reduce flushing, a common side effect of niacin) to statin treatment in…”
MethodAgain, Niacin Proves Ineffective in Statin-Treated Patients with Vascular Disease
Brett, A. S. (2014) · Journal watch · doi:10.1056/nejm-jw.na35071
Tsujita, K., Sugiyama, S., Shimomura, H., Yamanaga, K., Kaikita, K., Hokimoto, S., & Ogawa, H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.041
Icosapent ethyl in hypertriglyceridaemia: a guide to its use
Lyseng-Williamson, K. A., McCormack, P. L., & Kim, E. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0278-5
Hypercholestérolémie familiale Révision du diagnostic, du dépistage et du traitement
Turgeon, R. D., Barry, A. R., & Pearson, G. J. (2016) · PubMed Central
Agricultural Development in Asia
Hunsberger, W. S., Shand, R. T., & Brown, L. R. (1971) · Technology and Culture · doi:10.2307/3102313
From statin efficacy to everyday effectiveness: Studying the gap in between.
Ruokoniemi, P. T. (2015) · UTUPub (University of Turku) · Cited by 2
Newer targets and therapies for hypertension and dyslipidemia in diabetic patients
Aronow, W. S. (2014) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000043
Conclusions and Take Home Message
Banach, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_17
LDL-cholestérol et incidence de diabète : étude de la « Framingham Heart Study »
Cauchi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30093-1
Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK9 Inhibitors.
Roncevic, S. M., Gobić, D., Jurjević, T. Z., Miculinić, Ž. R., & Zaputović, L. (2016) · Cardiologia Croatica · doi:10.15836/ccar.2016.330
Saeedi, R., Li, M., Rankin, S. J. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.001
8. Sphingosine-1-phosphate-rich high-density lipoprotein in cardiovascular health and disease
Egom, E. E. A. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-821-6_8
Lipid Guidelines: What’s Best for My Patient?
Sisson, E. M. (2016) · AADE in Practice · doi:10.1177/2325160316658094
Trastornos del metabolismo lipídico
García-Díaz, J. D. D., Latorre, J. M. M., Parra, A. R. V., & Fernández, D. C. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.019 · Cited by 1
When is OTC niacin appropriate?
Renfro, C. P. (2016) · Pharmacy Today · doi:10.1016/j.ptdy.2016.11.006
Ischemic Heart Disease in Diabetes
Saely, C. H., Vathie, K., & Drexel, H. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch44
Interventions to increase apolipoprotein A-I transcription in HepG2 cells
van der Krieken (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170330svdk
Editorial commentary: Importance of triglycerides
Jones, A. F. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.04.002
PharmacotherapyFirst: A Multimedia Learning Resource
Munyer, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst
Cioni, G. (2017) · Annals of Clinical Endocrinology and Metabolism · doi:10.29328/journal.hcem.1001001
“According to results of HPS2-THRIVE Study [10], nicotinic acid/ laropiprant had been withdrawn from the market in 2013, and patient suspended this therapy.”
ResultUtkina, E. A., Afanasieva, O. I., Artemyeva, N. V., Владиславович, Е. М., & Pokrovsky, S. N. (2017) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2017-5-91-96
Rached, F. H., Rocha, V. Z., Santos, R. D., Junior, C. V. S., & Caixeta, A. M. (2017) · Coronary Artery Disease · doi:10.1097/mca.0000000000000524
Diabète de type2 etdyslipidémie
Ziegler, O., & Böhme, P. (2017) · doi:10.1016/b978-2-294-74646-8.00019-5
Jung, C. H. (2017) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2017.6.1.8
The target level and the difference of pathway on lipid lowering therapy
Fujisue, K., & Tsujita, K. (2017) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.23.024
Wehling, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800687-0.00034-7
Propuesta personal de actualización para el tratamiento de la hipercolesterolemia en Colombia
Merchan-V, A. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.10.002
Statin Intolerance: Diagnosis and Management
Khanna, R., & Himanshu, D. (2017) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0037-1607193
Combined bioactive approach over atherosclerosis risk biomarkers
Scolaro, B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-07122017-163754
Hypertriglyceridemia: A new paradigm
Kannampilly, J. (2018) · Journal of Diabetology · doi:10.4103/jod.jod_22_17
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-1
Editorial commentary: Confessions of a drug dealer
Thompson, P. D. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.006
Primary Prevention of Atherosclerotic Cardiovascular Disease
Robinson, J. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00028-5 · Cited by 4
Genetic Association of Arterial Stiffness Index with Blood Pressure and Coronary Artery DiseasePreprint
Zekavat, S. M., Haas, M., Aragam, K. G., Emdin, C. A., Khera, A. V., Klarin, D. M., Zhao, H., & Natarajan, P. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/453878
Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases
Yamashita, S. (2018) · Health Evaluation and Promotion · doi:10.7143/jhep.45.755
Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines
Djordjevic, D. B., Đorđević, A. D., & Lović, D. B. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00173-w
Maleki, M., & Hosseini, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00016-x
Silaruks, S., Sriratanasathavorn, C., Rawdaree, P., Kunjara-Na-Ayudhya, R., Thinkhamrop, B., & Sritara, P. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82355
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Thomas, D. G. (2019) · Columbia Academic Commons (Columbia University) · doi:10.7916/d8-5wc2-4f04
Hyperglycémies iatrogènes en dehors du virus de l'immunodéficience humaine
Blicklé, J.-F., Tebacher, M., & Monassier, L. (2017) · Time to knit · doi:10.1016/s1155-1941(17)56362-3
High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
Groberg, D. H. (1992) · PubMed
Genetic disorders of lipoprotein metabolism
Bhatnagar, D., Schofield, J. D., & Soran, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00014-9 · Cited by 3
Thompson, P. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_9
Atherogenic dyslipidemia typical for metabolic syndrome
Blaha, V., Víšek, J., & Lášticová, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.003
Rohatgi, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00008-x · Cited by 1
What has changed in treatment of patients with dyslipidemia
Kyselák, O., & Soška, V. (2017) · Interní medicína pro praxi · doi:10.36290/int.2017.020
Statins in primary prevention: is the enthusiasm justified?
Chopra, A. K., & Yadav, R. K. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.07.021
Lira, A. L. D. A. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-28102020-155412
Hot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30024-8 · Cited by 1
The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
Rengarajan, R., Tecson, K. M., & McCullough, P. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_7
Prevention of Stroke by Lowering Blood Cholesterol Concentrations
Paciaroni, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316286234.017
Lipoprotein (a): Principles from Bench to Bedside
Koschinsky, M. L., & Boffa, M. B. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_19
Cardiovascular Disease in Women: Focus on Lipid Management
Morris, P. B., Aspry, K. E., Watson, K. E., Wild, R. A., & Bittner, V. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_24
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.